LANADELUMAB SAFETY AND IMMUNOGENICITY: RESULTS FROM THE PHASE 3 HELP STUDY

被引：1
|
作者：
Johnston, D.
Banerji, A.
Riedl, M.
Zuraw, B.
Lumry, W.
Bernstein, J.
Li, H.
Lu, P.
Hao, J.
Gower, R.
机构：
来源：
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY | 2018年 / 121卷 / 05期
关键词：
D O I：
10.1016/j.anai.2018.09.114
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
P166
引用
收藏
页码：S36 / S36
页数：1
相关论文
共 50 条
  • [41] Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study
    San-Miguel, J. F.
    Richardson, P. G.
    Sonneveld, P.
    Schuster, M. W.
    Irwin, D.
    Stadtmauer, E. A.
    Facon, T.
    Harousseau, J-L
    Ben-Yehuda, D.
    Lonial, S.
    Goldschmidt, H.
    Reece, D.
    Blade, J.
    Boccadoro, M.
    Cavenagh, J. D.
    Neuwirth, R.
    Boral, A. L.
    Esseltine, D-L
    Anderson, K. C.
    LEUKEMIA, 2008, 22 (04) : 842 - 849
  • [42] SAFETY OF LEMBOREXANT IN ELDERLY SUBJECTS WITH INSOMNIA: RESULTS FROM A PHASE 3 STUDY (SUNRISE 1)
    Rosenberg, Russell
    Filippov, Gleb
    LoPresti, Antonia
    Kumar, Dinesh
    Murphy, Patricia
    Moline, Margaret
    AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY, 2019, 27 (03): : S155 - S156
  • [43] Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study
    J F San-Miguel
    P G Richardson
    P Sonneveld
    M W Schuster
    D Irwin
    E A Stadtmauer
    T Facon
    J-L Harousseau
    D Ben-Yehuda
    S Lonial
    H Goldschmidt
    D Reece
    J Bladé
    M Boccadoro
    J D Cavenagh
    R Neuwirth
    A L Boral
    D-L Esseltine
    K C Anderson
    Leukemia, 2008, 22 : 842 - 849
  • [44] Updated safety results from phase 3 lecanemab study in early Alzheimer's disease
    Honig, Lawrence S.
    Sabbagh, Marwan N.
    van Dyck, Christopher H.
    Sperling, Reisa A.
    Hersch, Steven
    Matta, Andre
    Giorgi, Luigi
    Gee, Michelle
    Kanekiyo, Michio
    Li, David
    Purcell, Derk
    Dhadda, Shobha
    Irizarry, Michael
    Kramer, Lynn
    ALZHEIMERS RESEARCH & THERAPY, 2024, 16 (01)
  • [45] ATTACK-FREE STATUS DURING EXTENDED TREATMENT WITH LANADELUMAB FOR HEREDITARY ANGIOEDEMA: HELP OLE STUDY FINAL RESULTS
    Riedl, M.
    Johnston, D.
    Lumry, W.
    Bernstein, J.
    Nurse, C.
    Yu, M.
    Maurer, M.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2020, 125 (05) : S23 - S23
  • [46] Immunogenicity and safety of a NeuGcGM3 based cancer vaccine Results from a controlled study in metastatic breast cancer patients
    Mulens, Vladimir
    de la Torre, Ana
    Marinello, Patricia
    Rodriguez, Ronald
    Cardoso, Jorge
    Diaz, Rene
    O'Farrill, Miguel
    Macias, Amparo
    Viada, Carmen
    Saurez, Giselle
    Carr, Adriana
    Crombet, Tania
    Mazorra, Zaima
    Perez, Rolando
    Enrique Fernandez, Luis
    HUMAN VACCINES, 2010, 6 (09): : 736 - 744
  • [47] Long-term effectiveness and safety of lanadelumab in the US and Canada: Findings from the EMPOWER Study
    Johnston, Douglas
    Anderson, John
    Brouwer, Emily
    Andriotti, Tomas
    Fei, Kezhin
    Busse, Paula
    Bernstein, Jonathan
    Zuraw, Bruce
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2022, 149 (02) : AB165 - AB165
  • [48] EFFICACY AND SAFETY OF INCOBOTULINUMTOXINA FOR THE TREATMENT OF SIALORRHEA: RESULTS OF THE MAIN PHASE OF A PHASE 3 STUDY
    Jost, Wolfgang H.
    Michel, Olaf
    Oehlwein, Christian
    Slawek, Jaroslaw
    Bogucki, Andrzej
    Ochudlo, Stanislaw
    Banach, Marta
    Pagan, Fernando
    Flatau-Baque, Birgit
    Csikos, Janos
    Blitzer, Andrew
    TOXICON, 2018, 156 : S53 - S53
  • [49] Immunogenicity, safety, and efficacy of rurioctocog alfa pegol in previously untreated patients with severe hemophilia A: interim results from a phase 3, prospective, multicenter, open-label study
    Sidonio, Robert F.
    Thompson, Alexis A.
    Peyvandi, Flora
    Stasyshyn, Oleksandra
    Yeoh, Seoh Leng
    Sosothikul, Darintr
    Antmen, Ali Bulent
    Maggiore, Caterina
    Engl, Werner
    Ewenstein, Bruce
    Tangada, Srilatha
    EXPERT REVIEW OF HEMATOLOGY, 2023, 16 (10) : 793 - 801
  • [50] Real-world effectiveness and safety of lanadelumab for prophylaxis of hereditary angioedema attacks: 2-year interim results from the enable study
    Saguer, I. Martinez
    Cancian, M.
    Kinaciyan, T.
    Kessel, A.
    Andriotti, T.
    Botha, J.
    Wuillemin, W.
    ALLERGY, 2023, 78 : 27 - 28
12345